Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam following Intravenous Administration of ETX2514SUL to Healthy Adult Subjects

• Published in: Antimicrobial agents and chemotherapy Vol. 62; no. 11
• Main Authors: Rodvold, Keith A., Gotfried, Mark H., Isaacs, Robin D., O'Donnell, John P., Stone, Emily
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 01.11.2018
• Subjects: Acinetobacter baumannii - drug effects; Acinetobacter Infections - blood; Acinetobacter Infections - drug therapy; Acinetobacter Infections - metabolism; Administration, Intravenous; Adult; Anti-Bacterial Agents - administration & dosage; Anti-Bacterial Agents - blood; Anti-Bacterial Agents - metabolism; Azabicyclo Compounds; Azabicyclo Compounds - administration & dosage; Azabicyclo Compounds - blood; Azabicyclo Compounds - metabolism; Bronchoalveolar Lavage - methods; Bronchoalveolar Lavage Fluid - microbiology; Female; Healthy Volunteers; Humans; Macrophages, Alveolar - microbiology; Male; Middle Aged; Pharmacology; Pulmonary Alveoli - microbiology; Sulbactam; Sulbactam - administration & dosage; Sulbactam - blood; Sulbactam - metabolism; ETX2514SUL; pharmacokinetics; ETX2514; epithelial lining fluid; sulbactam; alveolar macrophages

ETX2514 is a novel β-lactamase inhibitor that broadly inhibits Ambler class A, C, and D β-lactamases. ETX2514 combined with sulbactam (SUL) in vitro restores sulbactam activity against Acinetobacter baumannii . ETX2514 is a novel β-lactamase inhibitor that broadly inhibits Ambler class A, C, and D β...